Literature DB >> 29619615

Dysfunctional γ-Secretase in Familial Alzheimer's Disease.

Michael S Wolfe1.   

Abstract

Genetics strongly implicate the amyloid β-peptide (Aβ) in the pathogenesis of Alzheimer's disease. Dominant missense mutation in the presenilins and the amyloid precursor protein (APP) cause early-onset familial Alzheimer's disease (FAD). As presenilin is the catalytic component of the γ-secretase protease complex that produces Aβ from APP, mutation of the enzyme or substrate that produce Aβ leads to FAD. However, the mechanism by which presenilin mutations cause FAD has been controversial, with gain of function and loss of function offered as binary choices. This overview will instead present the case that presenilins are dysfunctional in FAD. γ-Secretase is a multi-functional enzyme that proteolyzes the APP transmembrane domain in a complex and processive manner. Reduction in a specific function-the carboxypeptidase trimming of initially formed long Aβ peptides containing most of the transmembrane domain to shorter secreted forms-is an emerging common feature of FAD-mutant γ-secretase complexes.

Entities:  

Keywords:  Amyloid; Biochemistry; Genetics; Protease

Mesh:

Substances:

Year:  2018        PMID: 29619615      PMCID: PMC6592691          DOI: 10.1007/s11064-018-2511-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  53 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.

Authors:  W P Esler; W T Kimberly; B L Ostaszewski; T S Diehl; C L Moore; J Y Tsai; T Rahmati; W Xia; D J Selkoe; M S Wolfe
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

3.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

Authors:  J Näslund; V Haroutunian; R Mohs; K L Davis; P Davies; P Greengard; J D Buxbaum
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

4.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.

Authors:  M S Wolfe; W Xia; B L Ostaszewski; T S Diehl; W T Kimberly; D J Selkoe
Journal:  Nature       Date:  1999-04-08       Impact factor: 49.962

5.  The role of presenilin cofactors in the gamma-secretase complex.

Authors:  Nobumasa Takasugi; Taisuke Tomita; Ikuo Hayashi; Makiko Tsuruoka; Manabu Niimura; Yasuko Takahashi; Gopal Thinakaran; Takeshi Iwatsubo
Journal:  Nature       Date:  2003-03-16       Impact factor: 49.962

6.  Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production.

Authors:  Tobias Moehlmann; Edith Winkler; Xuefeng Xia; Dieter Edbauer; Jill Murrell; Anja Capell; Christoph Kaether; Hui Zheng; Bernardino Ghetti; Christian Haass; Harald Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

7.  A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing.

Authors:  Andreas Weidemann; Simone Eggert; Friedrich B M Reinhard; Markus Vogel; Krzysztof Paliga; Gottfried Baier; Colin L Masters; Konrad Beyreuther; Geneviève Evin
Journal:  Biochemistry       Date:  2002-02-26       Impact factor: 3.162

8.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Authors:  L F Lue; Y M Kuo; A E Roher; L Brachova; Y Shen; L Sue; T Beach; J H Kurth; R E Rydel; J Rogers
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

9.  Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.

Authors:  Y M Li; M Xu; M T Lai; Q Huang; J L Castro; J DiMuzio-Mower; T Harrison; C Lellis; A Nadin; J G Neduvelil; R B Register; M K Sardana; M S Shearman; A L Smith; X P Shi; K C Yin; J A Shafer; S J Gardell
Journal:  Nature       Date:  2000-06-08       Impact factor: 49.962

10.  Charge states rather than propensity for beta-structure determine enhanced fibrillogenesis in wild-type Alzheimer's beta-amyloid peptide compared to E22Q Dutch mutant.

Authors:  Francesca Massi; D Klimov; D Thirumalai; John E Straub
Journal:  Protein Sci       Date:  2002-07       Impact factor: 6.725

View more
  7 in total

Review 1.  Unraveling the complexity of γ-secretase.

Authors:  Michael S Wolfe
Journal:  Semin Cell Dev Biol       Date:  2020-01-21       Impact factor: 7.727

Review 2.  RIP at the Synapse and the Role of Intracellular Domains in Neurons.

Authors:  Yan Jun Lee; Toh Hean Ch'ng
Journal:  Neuromolecular Med       Date:  2019-07-25       Impact factor: 3.843

Review 3.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

4.  γ-Secretase as a drug target for familial Alzheimer's disease: the road less traveled.

Authors:  Michael S Wolfe
Journal:  Future Med Chem       Date:  2022-08-30       Impact factor: 4.767

5.  An internal docking site stabilizes substrate binding to γ-secretase: Analysis by molecular dynamics simulations.

Authors:  Shu-Yu Chen; Martin Zacharias
Journal:  Biophys J       Date:  2022-05-20       Impact factor: 3.699

6.  Inhibitory proteins block substrate access by occupying the active site cleft of Bacillus subtilis intramembrane protease SpoIVFB.

Authors:  Sandra Olenic; Lim Heo; Michael Feig; Lee Kroos
Journal:  Elife       Date:  2022-04-26       Impact factor: 8.713

7.  Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.

Authors:  Jasmeer P Chhatwal; Stephanie A Schultz; Eric McDade; Aaron P Schultz; Lei Liu; Bernard J Hanseeuw; Nelly Joseph-Mathurin; Rebecca Feldman; Colleen D Fitzpatrick; Kathryn P Sparks; Johannes Levin; Sarah B Berman; Alan E Renton; Bianca T Esposito; Maria Vitoria Fernandez; Yun Ju Sung; Jae Hong Lee; William E Klunk; Anna Hofmann; James M Noble; Neill Graff-Radford; Hiroshi Mori; Steven M Salloway; Colin L Masters; Ralph Martins; Celeste M Karch; Chengjie Xiong; Carlos Cruchaga; Richard J Perrin; Brian A Gordon; Tammie L S Benzinger; Nick C Fox; Peter R Schofield; Anne M Fagan; Alison M Goate; John C Morris; Randall J Bateman; Keith A Johnson; Reisa A Sperling
Journal:  Lancet Neurol       Date:  2022-02       Impact factor: 44.182

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.